Success Metrics

Clinical Success Rate
95.8%

Based on 23 completed trials

Completion Rate
96%(23/24)
Active Trials
1(3%)
Results Posted
35%(8 trials)
Terminated
1(3%)

Phase Distribution

Ph not_applicable
2
7%
Ph early_phase_1
1
3%
Ph phase_4
6
21%
Ph phase_1
7
24%
Ph phase_2
8
28%
Ph phase_3
4
14%

Phase Distribution

8

Early Stage

8

Mid Stage

10

Late Stage

Phase Distribution28 total trials
Early Phase 1First-in-human
1(3.6%)
Phase 1Safety & dosage
7(25.0%)
Phase 2Efficacy & side effects
8(28.6%)
Phase 3Large-scale testing
4(14.3%)
Phase 4Post-market surveillance
6(21.4%)
N/ANon-phased studies
2(7.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

95.8%

23 of 24 finished

Non-Completion Rate

4.2%

1 ended early

Currently Active

1

trials recruiting

Total Trials

29

all time

Status Distribution
Active(1)
Completed(23)
Terminated(1)
Other(4)

Detailed Status

Completed23
unknown3
Suspended1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
29
Active
1
Success Rate
95.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (3.6%)
Phase 17 (25.0%)
Phase 28 (28.6%)
Phase 34 (14.3%)
Phase 46 (21.4%)
N/A2 (7.1%)

Trials by Status

completed2379%
suspended13%
recruiting13%
unknown310%
terminated13%

Recent Activity

1 active trials
Showing 5 of 29
recruitingphase_2

Alpha-1 Blockade for Alcohol Use Disorder (AUD)

NCT04135846
completedearly_phase_1

Doxazosin an a1 Antagonist for Alcohol Dependence

NCT01437046
suspendedphase_2

Treating Nightmares in Posttraumatic Stress Disorder With Clonidine and Doxazosin

NCT05360953
completedphase_4

Doxazosin and Ramipril in Hypertension

NCT02901977
completedphase_4

Phenoxybenzamine Versus Doxazosin in PCC Patients

NCT01379898
View all 29 trials

Clinical Trials (29)

Showing 20 of 29 trialsScroll for more
NCT04135846Phase 2

Alpha-1 Blockade for Alcohol Use Disorder (AUD)

Recruiting
NCT01437046Early Phase 1

Doxazosin an a1 Antagonist for Alcohol Dependence

Completed
NCT05360953Phase 2

Treating Nightmares in Posttraumatic Stress Disorder With Clonidine and Doxazosin

Suspended
NCT02901977Phase 4

Doxazosin and Ramipril in Hypertension

Completed
NCT01379898Phase 4

Phenoxybenzamine Versus Doxazosin in PCC Patients

Completed
NCT00006294

Genetics of Hypertension Associated Treatments (GenHAT)

Completed
NCT03176693Phase 3

Preoperative Alpha Blockade for Pheochromocytoma

Completed
NCT02308202Phase 1

DOXAZOSIN FOR PTSD

Completed
NCT02538744Phase 1

Complementary Combination Therapy for Cocaine Dependence

Completed
NCT02500602Phase 2

CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders

Completed
NCT02989493Phase 2

Testing Doxazosin to Treat Stress Mechanisms in Alcoholism

Completed
NCT00535925Phase 4

Nephropathy In Type 2 Diabetes and Cardio-renal Events

Completed
NCT01953432Phase 2

Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse

Completed
NCT00880997Phase 1

The Efficacy of Doxazosin for Cocaine Users

Completed
NCT01145183Phase 2

Pharmacogenetics of Doxazosin for Cocaine Dependence

Completed
NCT01386177Phase 1

Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)

Completed
NCT00021814Phase 3

Medical Therapy of Prostatic Symptoms

Completed
NCT02785393Phase 1

DOX as a Potential Treatment for Methamphetamine Dependence

Completed
NCT00000542Phase 3

Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Completed
NCT02563405Phase 2

The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
29